Alembic Pharmaceuticals Gains USFDA Final Approval for Oseltamivir Phosphate, Targeting $27M Flu Market

Alembic Pharmaceuticals Limited is making headlines again with another significant win in the highly competitive U.S. generics market. The Vadodara-headquartered pharma giant announced on June 26, 2026, that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. This marks a crucial expansion of Alembic’s product portfolio and reinforces its strong commitment to the U.S. market.

The approved Oseltamivir Phosphate is therapeutically equivalent to Hoffmann-La Roche, Inc.’s Tamiflu Oral Suspension, a well-known influenza neuraminidase inhibitor. It is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged two weeks and older, and for prophylaxis in patients aged one year and older. This approval positions Alembic to tap into a vital segment of the healthcare market, particularly as flu seasons remain a persistent public health concern.

The financial implications of this approval are noteworthy.

Key Market Opportunity:

• **Target Market Size:** Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, holds an estimated market size of US$ 27 million for the twelve months ending March 2026, according to IQVIA data.

This opens a valuable revenue stream for Alembic, providing a fresh impetus for growth. The approval further solidifies Alembic’s robust presence in the US, adding to its impressive track record of 243 cumulative ANDA approvals, comprising 223 final approvals and 20 tentative approvals. Such consistent regulatory success underscores Alembic’s strong R&D capabilities and its ability to navigate complex regulatory pathways effectively.

For investors, this latest approval signals continued growth potential and a diversified product pipeline for Alembic Pharmaceuticals, reinforcing its status as a key player in the global generics landscape. This strategic move strengthens its footprint and promises positive momentum moving forward.